Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Brain Neoplasms 3Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 73Bevacizumab 58Radiotherapy 40Radiosurgery 28Carboplatin 23Nivolumab 17Etoposide 17Cisplatin 17pembrolizumab 16Irinotecan 16Ipilimumab 15Magnetic Resonance Spectroscopy 14Erlotinib Hydrochloride 14Cyclophosphamide 14Carmustine 14Pemetrexed 13Topotecan 10Surgical Procedures, Operative 10Capecitabine 10Lapatinib 9Filgrastim 9Trastuzumab 8Thalidomide 8Sunitinib 8Paclitaxel 8Lomustine 8Aminolevulinic Acid 8encorafenib 7binimetinib 7Vincristine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Brain Neoplasms × 5-fluoropentyl-2-methylmalonic acid × Clear all
NCT00696943 2013-02-15

18F ML-10 for Early Detection of Response of Brain Metastases to SRS

Aposense Ltd.

Phase 2 Terminated
1 enrolled
CNS

Brain Neoplasms

NCT00791063 2013-02-13

18F ML-10 for Early Detection of Response of Brain Metastases to WBRT

Aposense Ltd.

Phase 2 Completed
10 enrolled
CNS

Brain Neoplasms

NCT00805636 2010-05-12

Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.

Aposense Ltd.

Phase 2 Unknown
30 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡